Replimune Group Inc(REPL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.28 | Insider Own | 5.95% | Shs Outstand | 94.2M | Perf Week | 12.85% |
| Market Cap | 1.17B | Forward P/E | - | EPS next Y | 33.89% | Insider Trans | -3.19% | Shs Float | 88.6M | Perf Month | 0.89% |
| Enterprise Value | 1.09B | PEG | - | EPS next Q | -0.78 | Inst Own | 103.04% | Short Float | 26.1% | Perf Quarter | 133.08% |
| Income | -0.30B | P/S | - | EPS this Y | 14.6% | Inst Trans | 18.6% | Short Ratio | 5.84 | Perf Half Y | 365.3% |
| Sales | 0.00B | P/B | 9.91 | EPS next 5Y | 40.56% | ROA | -82.28% | Short Interest | 23.13M | Perf YTD | 28.29% |
| Book/sh | 1.26 | P/C | 6.02 | EPS past 3/5Y | -4.15% -14.11% | ROE | -134.29% | 52W High | -23.64% ($16.33) | Perf Year | 41.7% |
| Cash/sh | 2.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | -139.06% | 52W Low | 731.33% ($1.50) | Perf 3Y | -14.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.95% | Gross Margin | - | Volatility(W/M) | 6.39% 6.28% | Perf 5Y | -57.01% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.78 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.23 | EPS Q/Q | 23.97% | Profit Margin | - | RSI (14) | 50.36 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.23 | Sales Q/Q | - | SMA20 | 0.52% ($12.41) | Beta | 1 | Target Price | $19.43 |
| Payout | - | Debt/Eq | 1.06 | Earnings | 2026/10/28 | SMA50 | -7.49% ($13.48) | Rel Volume | 0.52 | Prev Close | $11.46 |
| Employees | 465 | LT Debt/Eq | 1.02 | EPS/Sales Surpr. | -3.75% - | SMA200 | 36.33% ($9.15) | Avg Volume(3M) | 3.96M | Price | $12.47 |
| IPO | 2018/7/20 | Option/Short | Yes/Yes | Trades | 14685 | Volume | 2,045,866 | Change | 8.81% |
🧬 Replimune Group (REPL) is a US biotech company developing immune oncology therapies based on tumor-dissolving (oncolytic) viruses. Founded in 2015, the company is researching treatments for solid tumors such as melanoma using its RPx platform, which combines an engineered herpes simplex virus with immune-modulating genes. This approach aims to directly activate anti-cancer immune responses within the tumor itself, and Replimune is pursuing combination strategies with existing immune checkpoint inhibitors.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
Next earnings report: October 28
1 days to go.
REPL has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.6% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -57.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #146 of 594 in the industry
Based on market cap of $1B.
DRTS#142 Alpha Tau Medical Ltd $1B PER - 
KARD#143 Kardigan Inc $1B PER - 
SNDX#144 Syndax Pharmaceuticals Inc $1B PER - 
OMER#145 Omeros Corp $1B PER 11.3 REPL#146 Replimune Group Inc $1B PER - 
FAQ
What kind of company is REPL?
REPL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of REPL?
The market cap of REPL is approximately $1.2B, ranking 2,444 within its sector.
What is the 52-week high and low for REPL?
REPL has recorded a 52-week high of $16.33 and a low of $1.50.
